74 results about "TGF beta 1" patented technology

The present invention includes the selection and isolation of thioaptamers that target the signaling protein TGF-β1, compositions of such thioaptamers and the use of such thioaptamers to either block or enhance signal transduction of the TGF-β1 protein and thus function as, e.g., immunomodulatory agents. Thioaptamers may also be targeted alone or in combination with other thioaptamers against the ligand, the receptors, the ligand trap protein(s) and / or the co-receptors to modulate TGF-β signaling pathway.

A pharmaceutical composition comprising a prostaglandin such as misoprostol and TGF-B in amounts sufficient to stimulate production of chondrocyte matrix is disclosed which exhibit therapeutic synergy.

Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and / or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.

The invention relates to a medicament for treating idiopathic pulmonary fibrosis. Dried ginger, schisandra, seed of snakegourd, cassia twig, bupleurum, pinellia, codonopsis pilosula, radix glycyrrhizae preparata, ginger and jujube are used as raw material medicaments and can be prepared into any common oral preparation. The medicament of the invention has the efficacy of removing evil diseases, conditioning cold and heat, relating lung qi and relieving cough and asthma, and can be used for treating the idiopathic pulmonary fibrosis. Animal test results show that the medicament of the invention can relieve abnormal change of PF I rat lung tissue, regulate free radical metabolism in a model body of rat pulmonary fibrosis, enhance the activity of GSH-Px and S0D, reduce the content of MDA and NO and effectively reduce PDGF, TGF-beta 1 and TNF-a levels in blood serum, and has the functions of preventing and treating pulmonary damage and fibrosis caused by bleomycin. Clinical tests prove that the total effective rate of the medicament for treating the idiopathic pulmonary fibrosis is up to 88.5%.

Pharmaceutical composition comprising a chemotherapeutic agent and a TGF-beta antisense oligonucleotide, wherein the antisense oligonucleotide reduces the sensitivity and IC50, respectively, of the cytotoxicity of the chemotherapeutic agent. Preferably, the antisense oligonucleotide is a TGF-beta 1, 2, and / or 3 antisense oligonucleotide and the chemotherapeutic agent is preferably gemcitabine, 5-fluorouracil, temozolomide, dacarbacine, docetaxel, cisplatin, oxaliplatin, tamoxifen, or irinotecan.

The invention relates to a drug application of a chemical substance wedelolactone for treatment of pulmonary fibrosis. The chemical substance wedelolactone is derived from a traditional Chinese medicine eclipta, and the structure is determined through spectral data; the wedelolactone can significantly improve the degree of model mouse lung tissue pulmonary fibrosis after intragastric administration, reduce NO (Nitrogen Oxide) and MDA (Methylene dioxyamphetamine) contents reflecting degree of lung injury, HYP (Hydroxyproline) content reflecting collagen deposition in the lung tissues, and cell factor TGF-beta 1 (Transforming Growth Factor) content causing pulmonary fibrosis, and inhibit human embryo lung fibroblast proliferation in vitro and HYP content of the human embryo lung fibroblast. In-vivo and in-vitro experiments show that wedelolactone can obviously improve bleomycin induced mouse pulmonary fibrosis, so that the wedelolactone can be taken as a novel drug for treating pulmonary fibrosis.

The invention provides a defined low protein culture medium for maintaining cells in an undifferentiated state, the medium comprising: a basal medium, an organic acid from the tricarboxylic acid cycle, nonessential amino acids, a combination of growth factors selected from the group consisting of FGF-2 protein, an IGF-1 protein or insulin, a Transferrin protein, and a TGF beta 1 protein, wherein the medium is essentially feeder-free, essentially xeno-free, essentially free of beta-mercaptoethanol, and essentially free of animal-derived or human-derived proteins.

The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.

The invention relates to application of captopril to the preparation of medicaments for treating and / or inhibiting scar hyperplastic diseases. Particularly, the hyperplastic diseases comprise hyperplastic scar, cheloid, urethral scar stricture and silicon gel breast augmentation prosthesis postoperative capsular contracture. When the diseases are treated, the captopril is used as an active ingredient, clinically-used emulsifiable paste, gel, injection and the like in different formulations are prepared by the conventional preparation process. The study indicates that the captopril can reduce the capacity of synthesizing pathologic scar fibroblast collagen and secreting the collagen, weaken the multiplication capacity of fibroblasts and reduce the expression of transforming growth factor-beta 1 (TGF-beta 1), and has a good treatment or prevention effect on pathologic scars. Simultaneously, the captopril acts on scar tissue directly, has the advantages of small dose, high curative effect, small side effect, mature raw material process, readily available materials, low cost and the like, and is expected to become a main medicament for treating and preventing the scars clinically.

The invention discloses an application of glycosyl modified polyphenol compounds as drugs for relieving paraquat poisoning and treating pulmonary fibrosis. The glycosyl modified polyphenol compounds have the structure shown in the description. The glycosyl modified polyphenol compounds have a good oxidation resistance function and a lung protection function and have a notable protection function on lung injury caused by paraquat, and a mechanism is related with reduction of formation of oxygen radicals, relieving of oxidative stress and inflammatory reaction, increase of content of GSH in blood serum and SOD in lung tissue and reduction of content of MDA and HYP in lung tissue. The glycosyl modified polyphenol compounds can effectively inhibit bleomycin-induced pulmonary fibrosis of mice,and the mechanism is related with reduction of expression of TGF-beta 1, IL-6, alpha-SMA, P-smad2, type I collagen and type III collagen in lung tissue, increase of content of GSH and SOD in blood serum and reduction of the content of HYP in lung tissue.

The invention discloses a cosmetic composition. The cosmetic composition contains effective ingredients and cosmetic auxiliaries, wherein the effective ingredients include fucoidin, TGF-beta 1, IGF-I and EGF. The invention also provides a method for preparing the cosmetic composition. The invention also provides an application of the composition in preparing cosmetics, wherein the composition contains fucoidin, TGF-beta 1, IGF-I and EGF. Through the technical scheme above, the composition disclosed by the invention overcomes the defect that the combination of macromolecular polysaccharides in cosmetic products and various cytokines easily is likely to cause skin hypersensitivity; and by using the composition, fucoidin can take the best moisturizing effect, and in cooperation with various cytokines, multiple cosmetic effects such as eliminating fine wrinkles, removing scars, and the like are produced.

The invention discloses an effective method for differentiation induction from hPSCs to MSCs. The effective method comprises the following steps: 1) after transferring a hPSCs cell strain which is notdifferentiated on a culture plate coated with an extracellular matrix and culturing, culturing by using a differentiation culture medium which contains BMP-SMAD1 / 5 / 8 signal channel activator, a TGF-beta 1 / Activin / Nodal-SMAD2 / 3 signal channel activator, a Wnt activator and a PI3K inhibitor; 2) removing an old culture medium, and continuing to culture by using a differentiation culture medium whichcontains a TGF-beta1 / Activin / Nodal-SMAD2 / 3 signal channel inhibitor; 3) dissociating and transferring cells to a new culture plate, and continuing to culture by using a differentiation culture mediumwhich contains a TGF-beta1 / Activin / Nodal-SMAD2 / 3 signal channel inhibitor; and 3) dissociating and transferring cells to a wall-attached culture plate and continuing to culture so as to obtain MSCs.The complete scheme and method for differentiating into MSCs from hPSC in an oriented manner through a middle-section primitive streak stage or a side mesoderm stage is established in vitro. Comparedwith a conventional method, the effective method is simple in technical step, simple and easy to operate and high in reproducibility, and MSCs with mature phenotype and high quality can be obtained within 12 days only.

The invention discloses a kit for screening colorectal cancer hereditary susceptibility genes. The kit comprises colorectal cancer susceptibility gene specificity primers for amplifying a plurality of target regions in a to-be-detected sample, wherein the colorectal cancer susceptibility genes include at least one of rs10795668, MMP2, SMAD7, ADH2, ALDH2, CYP1A2, MMP-1, MTHFR, TP53, VEGF, COX-2, DNMT3B, hMLH1, LOC727677, MMP9, MTRR and TGF-beta 1. The kit can detect a plurality of regions of the colorectal cancer susceptibility genes at the same time, detecting efficiency is improved, detecting cost is reduced, and detecting accuracy and sensitivity are high.

The invention discloses application of autovaccine preparation containing TGF beta 1. Adjuvant is added in the autovaccine preparation to prepare medicinal preparation for treating continuous pathogen infection of livestock. The vaccine preparation is fusion protein obtained by the way that part or total of the TGF beta 1 or part or total of mutant or total of similar gene sequences is recombined with at least one helper T cell capable of improving immunogenicity or the gene sequence of carrier protein to construct eukaryon or pronucleus expression plasmid and transform host cell for expression, or is directly prepared by eukaryon expression plasmid obtained by construction. The vaccine preparation can be directly used for preparing medicinal preparation for treating the continuous pathogen infection of livestock, induce domestic animals to generate antibody capable of neutralizing self TGF beta 1, and remove immunodepression function caused by too high level of TGF beta 1 in continuous process of infection; simultaneously, the vaccine preparation can depress the generation of inducible regulatory T cell at the persistent infection part of an organism, thus being beneficial to breaking the immune tolerance state of in-vivo pathogen by the organism and promoting the removing function of the organism on the continuously infectious pathogen.

The invention discloses a betulin derivative as well as a preparation method and application thereof. The structural formula of the betulin derivative provided by the invention is shown as a formula I, a formula II, a formula III, a formula IV, a formula V, a formula VI or a formula VII. According to the invention, the betulin is successfully subjected to structural modification by utilizing a microbial conversion technology, so that a plurality of novel compounds are obtained. In vitro TGF-beta 1 induced HK-2 cell experiments prove that the compounds have a relatively good protection effect on HK-2 cell damage. The compounds can be used as active ingredients of a medicine for preventing or treating nephropathy and have wide application.

The invention discloses a Nile tilapia transforming growth factor TGF-beta 1 gene, a related protein and application, and belongs to the technical field of biological genetic engineering. The nucleotide sequence of the Nile tilapia transforming growth factor TGF-beta 1 gene is expressed by SEQIDNO:1; and the amino acid sequence of the related protein TGF-beta 1 is expressed by SEQIDNO: 2. Prokaryotic expression of the mature peptide gene of the Nile tilapia transforming growth factor TGF-beta 1 is performed so that recombinant mature peptide of the Nile tilapia transforming growth factor beta 1; and after the mice are immunized by the mature peptide, corresponding polyclone antibodies can be obtained. The recombinant mature peptide of the Nile tilapia transforming growth factor beta 1 and the prepared polyclone antibodies can be further used as immune stimulants and used for scientific research.

The invention provides a medicinal composition for treating pulmonary fibrosis. The medicinal composition is prepared from the following raw medicinal materials in parts by weight: 30-40 parts of rhodiola rosea, 15-20 parts of panax notoginseng, 25-35 parts of salvia miltiorrhiza and 35-35 radix ophiopogonis. The invention also provides a preparation method and application of the medicinal composition. The medicinal composition can be used for effectively treating pulmonary fibrosis, improving related indexes of pulmonary fibrosis and reducing the contents of TGF-beta (transforming growth factor-beta) and TGF-beta 1 (transforming growth factor-beta 1) in liver tissues, so that the treatment effect of relieving the symptoms of pulmonary fibrosis to improve the survival quality can be achieved, the serious toxic and side effects of western chemical medicines can be avoided, and a new choice is provided for clinical administration.

Methods and devices are described for the regulation of BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA in stem cells via capacitive coupling or inductive coupling of specific and selective electric and / or electromagnetic fields to the bone cells or other tissues containing the stem cells, where the specific and selective fields are generated by application of specific and selective signals to field generating devices disposed with respect to the stem cells so as to facilitate the treatment of diseased or injured bone and other tissues. The resulting methods and devices are useful for the targeted treatment of osteoporosis, osteopenia, osteonecrosis, fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, and / or other conditions in which BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA and / or protein deficiencies in stem cells has been implicated.

The invention relates to application of patchouli alcohol in the preparation of drugs for prevention and treatment of renal injury and also provides a drug to antagonize renal fibrosis to prevent or / and treat hypertensive renal injury. The drug is mainly made from patchouli alcohol or patchouli oil, or with other drugs, as well as pharmaceutically acceptable accessories or accessory ingredients. The drug provided herein can inhibit renal fibrosis and retard renal injury by: inhibiting RAS (renin-angiotensin system), down-regulating TGF-beta 1 and PAI-1 levels, inhibiting the proliferation andactivation of MFB, reducing matrix protein synthesis and ECM (extracellular deposition) and improving pathogenic change in kidney tissue. Therefore, the patchouli alcohol based on renal fibrosis inhibition has excellent application prospect in the prevention or / and treatment renal injury, particularly in the development of drugs for hypertensive renal injury.

Methods and devices are described for the regulation of BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA in stem cells via capacitive coupling or inductive coupling of specific and selective electric and / or electromagnetic fields to the bone cells or other tissues containing the stem cells, where the specific and selective fields are generated by application of specific and selective signals to field generating devices disposed with respect to the stem cells so as to facilitate the treatment of diseased or injured bone and other tissues. The resulting methods and devices are useful for the targeted treatment of osteoporosis, osteopenia, osteonecrosis, fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, and / or other conditions in which BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA and / or protein deficiencies in stem cells has been implicated.

The invention relates to the technical field of medicine, in particular to the application of astragalus extract to preparation of NF-kappa B inhibitor. Experiments prove that the astragalus extract can inhibit chronic nephritis NF-kappa B expression and further affect the level of IL-6, TNF-alpha, TGF-beta 1 and MCP-1 and reduce proteinuria. Therefore, the astragalus extract can serve as an active component for inhibiting chronic kidney disease NF-kappa B and be used for preparing drugs for treating chronic kidney disease.

The invention belongs to the technical field of tissue engineering, particularly relates to an intervertebral disc tissue scaffold including agrowth factor and a preparation method thereof, and solves the technical problem by providing a tissue engineering scaffold for treating low back pain. The invention adopts the technical scheme that the intervertebral disc tissue scaffold including a growth factor is a coaxial electrospinning scaffold prepared by adopting the coaxial electrospinning technique, and the growth factor is TGF-beta 1. The invention further provides a preparation method of the intervertebral disc tissue scaffold. The intervertebral disc tissue scaffold can be used for treating low back pain.

The invention discloses application of saikoside d in preparation of anti-hepatic fibrosis disease drugs, and belongs to the technical field of medicines. The invention aims to provide pharmacological activities exhibited by the saikoside d in treatment of hepatic fibrosis symptoms and related mechanisms. The saikoside d has a good anti-hepatic fibrosis effect, and the action mechanisms may be related with improvement of activities of superoxide dismutase, reduction of generation of oxyradical and inhibition of activation of TGF-beta 1 (transforming growth factor) signaling pathway.

The invention belongs to biotechnology field and particularly relates to high throughput screening of an effective anti-hepatic fibrosis compound by means of picric acid-sirius red staining method on a collagenous fiber. The cell is hepatic stellate cell line CFSC-8B, transforming growth factor TGF-beta1 with the dose of 10ng / mL can obviously induce the CFSC-8B cell to secrete collagen when acting for 48 hours, and the secretion of the CFSC-8B cell collagen induced by the TGF-beta 1 can be effectively detected by means of picric acid-sirius red staining method. The picric acid-sirius red staining method on the collagenous fiber is applied to screening the compounds with anti-hepatic fibrosis activities in different polarity extracts of antrodia camphorata, ganoderma lucidum, cephalosporium sinensis, cordyceps mortierella, armillaria and hericium erinaceus powder. Tests prove that n-hexane and chloroform extract of the antrodia camphorata, ethyl acetate extract from the cordyceps mortierella, and n-hexane, chloroform extract and ethyl acetate extract from the armillaria can effectively inhibit the secretion of the CFSC-8B cell collagen induced by the TGF-beta 1, the above extracts have dose dependent relationship, are significant in difference, and have an anti-hepatic fibrosis function, and other extracts do not have significant inhibition effect.

The invention relates to application of a chemical substance Eupatilin for treating pulmonary fibrosis. The compound Eupatilin is obtained from traditional Chinese medicine Folium Artemisiae Argyi, the structure of the Eupatilin is determined according to spectrum data, the fibrosis degree of lung tissues of model mice is improved obviously after intragastric administration of the Eupatilin, NO content and MDA content which reflect lung damage degree are reduced, HYP content reflecting lung tissue collagen deposition is lowered, and the content of cell factor TGF-beta 1 causing the pulmonary fibrosis is decreased; human embryonic lung fibroblast proliferation and HYP content are inhibited in vitro. In-vivo and in-vitro experiments show that the Eupatilin can remarkably improve bleomycin induced pulmonary fibrosis of the mice, and can be applied to drugs for treating the pulmonary fibrosis.

The invention belongs to the field of medicines, and relates to application of dihydrotanshinone I in preparation of anti-hepatic fibrosis medicines. Systematic researches on the inhibiting effect on the mRNA and protein level of fibrosis main markers (COL1A1, TGFB1, ACTA2 and MMP2) in a TGF beta 1 induced LX-2 cell, influence on contents of ALT and AST in the serum of a BDL rat, improvement on the pathological change of liver tissues of the BDL rat, influence on the content of hydroxyproline of liver tissues of the BDL rat, inhibition on the mRNA and protein level of fibrosis main markers of liver tissues of a rat, influence on the hepatic fibrosis degree of the rat prove that the dihydrotanshinone I has excellent anti-hepatic fibrosis activity, and is expected to be developed into novel anti-hepatic fibrosis medicines.

The invention discloses a new application of a compound shown in a structural formula I in preparing medicaments for preventing and / or treating pulmonary fibrosis. The invention has a compound shown in the structural formula I, which can significantly reduce the inflammation indexes of pathologically changed pulmonary tissues, reduce the content of fibrosis-promoting factors TGF-beta 1 in pathologically changed pulmonary tissues, reduce the excessive deposition of collagens in pathologically changed pulmonary tissues, and has a significant prevention and treatment effect on pulmonary fibrosis.

The invention discloses an IL-1 beta vaccine for treating pulmonary fibrosis. A recombinant PfTrx-IL-1 beta vaccine established by inserting epitope of IL-1 beta into a PfTrx carrier sequence can successfully stimulate an organism to generate high-potency IL-1 beta resistant neutralizing antibody and can obviously relieve pulmonary fibrosis induced by bleomycin. Immunity of the IL-1 beta vaccine can obviously inhibit mouse pulmonary tissue collagen deposition, the vaccine can lower expression level of TGF-beta 1, CTGF and PDGFB in mouse, and these characteristics are highly conducive to slowing down the process of pulmonary fibrosis. Therefore, the IL-1 beta vaccine is expected to be developed into an effective means for treating pulmonary fibrosis.